Hamamatsu Pharma Research USA

MediciNova is a publicly traded biopharmaceutical company focused on acquiring and developing novel small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the United States market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which it believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. The company s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancer, generalized anxiety disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. Its current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline, MN-221 for the treatment of status asthmaticus and MN-166 for the treatment of multiple sclerosis. MediciNova maintains a location in San Diego, Calif.

Takeda San Diego is a U.S.-based center for discovery research operation that has a professional staff of more than 100 employees. The center integrates cutting-edge protein crystallography and drug discovery technologies for the treatment of metabolic diseases and cancer. Takeda San Diego utilizes structural biology capabilities to discover new drugs for the treatment of diabetes, cancer and other diseases. It is a part of Takeda Pharmaceutical Company Limited, which is one of the largest pharmaceutical companies in Japan. Takeda Pharmaceutical Company Limited provides oral diabetes medicines, as well as a variety of other pharmaceutical products. Takeda San Diego is located in San Diego, Calif.

MediciNova is a biopharmaceutical company based in San Diego, CA, dedicated to developing innovative therapies for neurology, respiratory, and liver diseases that currently lack effective treatment options. Their development pipeline includes MN-166, targeting progressive multiple sclerosis and amyotrophic lateral sclerosis (ALS); MN-221, focused on acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD); and MN-001, addressing fibrotic diseases such as liver fibrosis, non-alcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF).Generated from the website